Kevin Tan, MD
Ophthalmology · San Francisco, CANPI 1063654978
Payments from drug & device makers
Across 330 payments — averaging $29.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$3K
- AbbVie$1K
- Sight Sciences, Inc.$871
- Glaukos Corporation$520
- Carl Zeiss Meditec USA, Inc.$501
- Oyster Point Pharma, Inc.$451
- plus $3K from 20 others
What the payments were for
- Food & beverage$9,14695%
- Other$5015%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 91 | $2,889 |
| AbbVie(2 entities) | 60 | $1,437 |
| Sight Sciences, Inc. | 32 | $871 |
| Glaukos Corporation | 5 | $520 |
| Carl Zeiss Meditec USA, Inc. | 1 | $501 |
| Oyster Point Pharma, Inc. | 13 | $451 |
| Bausch & Lomb Americas Inc. | 15 | $329 |
| Novartis | 18 | $282 |
| Mallinckrodt Hospital Products Inc. | 9 | $270 |
| Tarsus Pharmaceuticals, Inc. | 10 | $265 |
| Aerie Pharmaceuticals, Inc. | 10 | $259 |
| Johnson & Johnson Surgical Vision, Inc. | 10 | $256 |
| Sun Pharmaceutical Industries Inc. | 10 | $204 |
| Biotissue Holdings Inc. | 5 | $179 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 8 | $174 |
| Kala Pharmaceuticals, Inc. | 8 | $161 |
| ANI Pharmaceuticals, Inc. | 8 | $154 |
| Thea Pharma Inc. | 6 | $129 |
| Dompe US, Inc. | 3 | $89 |
| Rxsight Inc | 2 | $47 |
| Carl Zeiss Meditec, Inc. | 1 | $44 |
| Ivantis, Inc | 1 | $40 |
| Coopervision Inc. | 1 | $32 |
| Philips North America LLC | 1 | $25 |
| Rayner Intraocular Lenses Limited | 1 | $21 |
| Eyevance Pharmaceuticals LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,647 in reported general payments places this provider in the 80th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 203 | $103,960 |
| RestasisCyclosporine | 110 | $79,719 |
| RocklatanNetarsudil Mesylat/Latanoprost | 119 | $62,660 |
| RhopressaNetarsudil Mesylate | 109 | $50,044 |
| Cyclosporine | 76 | $46,055 |
| XiidraLifitegrast | 41 | $38,112 |
| CequaCyclosporine | 38 | $30,747 |
| VyzultaLatanoprostene Bunod | 56 | $27,185 |
| TyrvayaVarenicline Tartrate | 30 | $26,775 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 99 | $23,430 |
| CombiganBrimonidine Tartrate/Timolol | 39 | $14,353 |
| Latanoprost | 998 | $9,860 |
| Brimonidine Tartrate | 159 | $8,988 |
| Timolol Maleate | 317 | $8,177 |
| Brinzolamide | 44 | $7,024 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan | $1,437 | $198,032352 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $259 | $112,704228 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $329 | $65,29697 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $204 | $30,74738 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $451 | $26,77530 claims |
| AlconSimbrinza | $2,889 | $23,43099 claims |
| Thea Pharma Inc.Iyuzeh | $129 | $4,38515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,513 ophthalmology providers in California.
Other ophthalmology in San Francisco
- Nisha AcharyaSan Francisco$33M
- Daniel SchwartzSan Francisco$8M
- Robert BhisitkulSan Francisco$778K
- Gaurav ShahSan Francisco$620K
- David WirtaNewport Beach$18.4M
- Michael IpPasadena$10.2M
- Raymond DouglasBeverly Hills$9.7M
- Sherif El HaraziGlendale$9.2M
- Nikolas Londonla Jolla$6.1M
- Michael BerlinWest Hollywood$5.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.